

# Kazuo Fujihara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3878176/publications.pdf>

Version: 2024-02-01

41  
papers

11,087  
citations

331670

21  
h-index

330143

37  
g-index

41  
all docs

41  
docs citations

41  
times ranked

8758  
citing authors

#	ARTICLE	IF	CITATIONS
1	Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. <i>Multiple Sclerosis Journal</i> , 2022, 28, 480-486.	3.0	32
2	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103356.	2.0	16
3	Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder. <i>Neurology and Therapy</i> , 2022, 11, 123-135.	3.2	21
4	Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAKuraSky: A case series. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103772.	2.0	8
5	Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD. <i>Journal of the Neurological Sciences</i> , 2022, 437, 120269.	0.6	5
6	Autoantibodies in central nervous system and neuromuscular autoimmune disorders: A narrative review. <i>Precision and Future Medicine</i> , 2022, 6, 105-116.	1.6	1
7	New therapies for neuromyelitis optica spectrum disorder. <i>Lancet Neurology</i> , The, 2021, 20, 60-67.	10.2	86
8	CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder. <i>Heliyon</i> , 2021, 7, e05899.	3.2	7
9	Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. <i>Journal of Neurology</i> , 2021, 268, 1938-1944.	3.6	24
10	Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102641.	2.0	26
11	Optic neuritis after ocular trauma in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. <i>Brain and Behavior</i> , 2021, 11, e02083.	2.2	2
12	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2052-2061.	3.0	11
13	Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder. <i>Neurology</i> , 2021, 97, e1-e12.	1.1	57
14	Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103222.	2.0	14
15	Distinctive lesions of brain MRI between MOG-antibody-associated and AQP4-antibody-associated diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 682-684.	1.9	9
16	White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments. <i>Scientific Reports</i> , 2021, 11, 22357.	3.3	17
17	Impact of intrathecal IgG synthesis on neurological disability in patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102382.	2.0	7
18	Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD. <i>Frontiers in Neurology</i> , 2020, 11, 932.	2.4	29

#	ARTICLE	IF	CITATIONS
19	Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Scientific Reports</i> , 2020, 10, 13890.	3.3	42
20	Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	112
21	Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody. <i>Journal of Neuroimmunology</i> , 2020, 349, 577431.	2.3	9
22	Perivenous demyelination: Association with anti-myelin oligodendrocyte glycoprotein antibody. <i>Clinical and Experimental Neuroimmunology</i> , 2020, 11, 22-27.	1.0	1
23	Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD). <i>Journal of the Neurological Sciences</i> , 2020, 410, 116671.	0.6	37
24	Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disorders. <i>Journal of Neuroimmunology</i> , 2020, 340, 577168.	2.3	11
25	Risk factors of attacks in neuromyelitis optica spectrum disorders. <i>Journal of Neuroimmunology</i> , 2020, 343, 577236.	2.3	24
26	Two Japanese cases of anti-MOG antibody-associated encephalitis that mimicked neuro-Behçet's disease. <i>Journal of Neuroimmunology</i> , 2019, 334, 577002.	2.3	12
27	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet, The</i> , 2019, 394, 1352-1363.	13.7	433
28	Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. <i>New England Journal of Medicine</i> , 2019, 381, 614-625.	27.0	536
29	Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. <i>New England Journal of Medicine</i> , 2019, 381, 2114-2124.	27.0	383
30	Children with myelin oligodendrocyte glycoprotein antibodies-associated disease: relation of phenotypes to central nervous system myelin maturation. <i>Developmental Medicine and Child Neurology</i> , 2018, 60, 339-340.	2.1	0
31	2017 Japanese guidelines for multiple sclerosis and neuromyelitis optica: Achievements and challenges. <i>Clinical and Experimental Neuroimmunology</i> , 2018, 9, 4-6.	1.0	0
32	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology, The</i> , 2018, 17, 162-173.	10.2	4,605
33	Nationwide epidemiological study of neuromyelitis optica in Japan. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 667-668.	1.9	42
34	MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Neurology</i> , 2018, 9, 217.	2.4	156
35	MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e322.	6.0	334
36	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e343.	6.0	55

#	ARTICLE	IF	CITATIONS
37	Whole brain and grey matter volume of Japanese patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017, 306, 68-75.	2.3	24
38	Different etiologies and prognoses of optic neuritis in demyelinating diseases. <i>Journal of Neuroimmunology</i> , 2016, 299, 152-157.	2.3	63
39	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2015, 85, 177-189.	1.1	3,275
40	Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. <i>Brain</i> , 2007, 130, 1235-1243.	7.6	561
41	Difference of anti-viral immunity induced by two mRNA vaccines: Implications in MS patients treated with anti-CD20-depleting therapy. <i>Clinical and Experimental Neuroimmunology</i> , 0, , .	1.0	0